Summit Therapeutics plc
("Summit" or the "Company")
EXERCISE OF OPTIONS
Oxford, UK, 13 May 2015 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that on 12 May 2015 it received notification of exercise in respect of options granted over 19,163 new ordinary shares of 1 penny each in the Company at an exercise price of 60 pence per share. Consequently the Company has issued and allotted 19,163 new ordinary shares in the Company.
An application has been made for the new ordinary shares to be admitted to AIM and admission is expected to occur on or around 18 May 2015. Following this issue of equity above, the Company's issued share capital will comprise of 61,001,744 ordinary shares of 1 penny each.
- END -
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection.
For more information, please contact:
Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski (US office) | Tel: +44 (0)1235 443 951 +1 617 294 6607 |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 |
N+1 Singer (Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781 235 3060 mavery@macbiocom.com |
Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |